Early determination of prognosis is very important in patients with HBV-ACLF, as it can be used to guide clinical management and to decrease the high short-term mortality rate.

 The MELD and the MELD-Na scores have been widely used to predict the outcome of end- stage liver disease.

 Recently, 2 large prospective multicentre cohorts of ACLF, the CANONIC study and the COSSH study, indicated that ACLF has regional phenotypic specificities due to the disease aetiology and precipitants.

 The aim of this study was to develop a new simplified prognostic score to accurately predict outcomes in patients with HBV-ACLF (and replace CLIF-C, ACLF (CLIFC ACLF) and the COSSH-ACLF scores.